Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Isaac Corro Ramos, Matthijs Versteegh, Rudolf A. de Boer, J Koenders, Gerard C.M. Linssen, Joan G. Meeder, Maureen Rutten‐van Mölken

Value in Health

HypertensionHeart FailureChronic Heart FailureCardiovascular DiseaseHealth PolicyHealth EconomicsAntihypertensive TherapyOutcomes ResearchPharmacoeconomicsCountry Adaptation AnalysisPharmacotherapyCardiac CareCost EffectivenessPublic HealthMedicineCardiology